| A hormone–DNA repair circuit governs the response to genotoxic insult JF Goodwin, MJ Schiewer, JL Dean, RS Schrecengost, R de Leeuw, ... Cancer discovery 3 (11), 1254-1271, 2013 | 384 | 2013 |
| A role for estrogen receptor phosphorylation in the resistance to tamoxifen R de Leeuw, J Neefjes, R Michalides International journal of breast cancer 2011, 2011 | 144 | 2011 |
| The hinge region of the human estrogen receptor determines functional synergy between AF-1 and AF-2 in the quantitative response to estradiol and tamoxifen W Zwart, R de Leeuw, M Rondaij, J Neefjes, MA Mancini, R Michalides Journal of cell science 123 (8), 1253-1261, 2010 | 133 | 2010 |
| Targeting cell cycle and hormone receptor pathways in cancer CES Comstock, MA Augello, JF Goodwin, R De Leeuw, MJ Schiewer, ... Oncogene 32 (48), 5481-5491, 2013 | 116 | 2013 |
| Novel actions of next-generation taxanes benefit advanced stages of prostate cancer R de Leeuw, LD Berman-Booty, MJ Schiewer, SJ Ciment, RB Den, ... Clinical Cancer Research 21 (4), 795-807, 2015 | 113 | 2015 |
| MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer R De Leeuw, C McNair, MJ Schiewer, NP Neupane, LJ Brand, ... Clinical Cancer Research 24 (17), 4201-4214, 2018 | 105 | 2018 |
| PARP‐1 regulates DNA repair factor availability MJ Schiewer, AC Mandigo, N Gordon, F Huang, S Gaur, R de Leeuw, ... EMBO molecular medicine 10 (12), e8816, 2018 | 62 | 2018 |
| Serine-305 phosphorylation modulates estrogen receptor alpha binding to a coregulator peptide array, with potential application in predicting responses to tamoxifen R Houtman, R de Leeuw, M Rondaij, D Melchers, D Verwoerd, ... Molecular cancer therapeutics 11 (4), 805-816, 2012 | 53 | 2012 |
| PKA phosphorylation redirects ERα to promoters of a unique gene set to induce tamoxifen resistance R De Leeuw, K Flach, C Bentin Toaldo, X Alexi, S Canisius, J Neefjes, ... Oncogene 32 (30), 3543-3551, 2013 | 47 | 2013 |
| A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov. 2013; 3: 1254–1271. doi: 10.1158/2159-8290 JF Goodwin, MJ Schiewer, JL Dean, RS Schrecengost, R de Leeuw, ... CD-13-0108.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 44 | |
| Patient-derived models reveal impact of the tumor microenvironment on therapeutic response AA Shafi, MJ Schiewer, R de Leeuw, E Dylgjeri, PA McCue, N Shah, ... European urology oncology 1 (4), 325-337, 2018 | 43 | 2018 |
| SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors A Yoshida, Y Bu, S Qie, J Wrangle, ER Camp, ES Hazard, G Hardiman, ... Science advances 5 (9), eaax6352, 2019 | 37 | 2019 |
| Pleiotropic impact of DNA-PK in cancer and implications for therapeutic strategies E Dylgjeri, C McNair, JF Goodwin, HK Raymon, PA McCue, AA Shafi, ... Clinical Cancer Research 25 (18), 5623-5637, 2019 | 28 | 2019 |
| Tumor cell heterogeneity and resistance; report from the 2018 Coffey‐Holden Prostate Cancer Academy Meeting AK Miyahira, RB Den, MI Carlo, R De Leeuw, TA Hope, F Karzai, ... The Prostate 79 (3), 244-258, 2019 | 17 | 2019 |
| Mutant p53 elicits context-dependent pro-tumorigenic phenotypes JJ McCann, IA Vasilevskaya, C McNair, P Gallagher, NP Neupane, ... Oncogene 41 (3), 444-458, 2022 | 14 | 2022 |
| A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov. 2013; 3: 1254–71 JF Goodwin, MJ Schiewer, JL Dean, RS Schrecengost, R de Leeuw, ... | 6 | |
| Abstract CT012: clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell cancer (HNSCC) EE Cohen, J Fayette, A Daste, C Even, CL Tourneau, I Brana, E Saada, ... Cancer Research 83 (8_Supplement), CT012-CT012, 2023 | 2 | 2023 |
| c15-153: Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naive prostate cancer that … WK Kelly, JL Godwin, JH Hoffman-Censits, KE Knudsen, R De Leeuw, ... Journal of Clinical Oncology 36 (6_suppl), TPS384-TPS384, 2018 | 2 | 2018 |
| Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer SF Slovin, K Knudsen, S Halabi, R de Leeuw, A Shafi, P Kang, S Wolf, ... Journal of Clinical Oncology 41 (32), 5015-5024, 2023 | 1 | 2023 |
| Abstract CT156: MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced gastric/esophageal adenocarcinoma (GEA) MD García, A Hollebecque, R Garcia-Carbonero, C Jungels, E Smyth, ... Cancer Research 83 (8_Supplement), CT156-CT156, 2023 | 1 | 2023 |
